Andere talen Apollomics, Inc.

Aandelen

APLM

KYG0411D1236

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 05-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,27 ^USD	+10,34%		+8,11%	+66,87%

19/11	Apollomics sluit schikkingsovereenkomst met twee minderheidsinvesteerders	RE
18/11	Apollomics kondigt wijzigingen aan in Raad van Bestuur en commissies, van kracht vanaf 16 november 2025	CI

Andere talen

Apollomics Announces Settlement of Cayman Litigation	19/11
Apollomics entered settlement agreement related to legal proceedings by two minority investors of co	19/11
Apollomics Announces Changes to its Board of Directors and Composition of Committees	18/11
Apollomics Announces Changes in Board and Committees, Effective from November 16, 2025	18/11
Apollomics received a payment of US$3.9 million from Launxp	21/10
Top Midday Gainers	16/10
Apollomics Receives Compliance Notification From Nasdaq	15/10
Apollomics announces continued listing on Nasdaq following hearing cancellation	15/10
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation	15/10
Nasdaq Resumes Trading in Apollomics Inc.	14/10
Apollomics says company has reversed its wind-up plans	14/10
Apollomics, Inc. Company Operational Continuity Update	14/10
Apollomics : Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain	23/09
Nasdaq Halts Apollomics Inc., Ltd.	17/09
Apollomics, Inc. Appoints Peter Lin as Chief Financial Officer, Effective September 4, 2025	05/09
Apollomics, Inc. Appoints Howard Chen as Chief Executive Officer, Effective September 4, 2025	05/09
Apollomics, Inc. Announces Board and Committee Changes	05/09
Apollomics, Inc. Announces Board Changes, Effective September 3, 2025	03/09
Apollomics, Inc. announced that it has received $4.088968 million in funding from Maxpro Investment Co., Ltd	03/09
Apollomics, Inc. announced that it expects to receive $4.088968 million in funding from Maxpro Investment Co., Ltd	02/09
Top Premarket Decliners	28/08
Apollomics Inc. Enters into an Agreement for the Development and Commercialization in Asia	25/07
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	03/04
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress	03/04
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia	31/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Apollomics, Inc.

Aandelen

APLM

KYG0411D1236

Biotechnologie & Medisch Onderzoek

Andere talen

Filters